Side-by-Side Comparison: Semaglutide vs Tirzepatide
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist only | Dual GLP-1 + GIP receptor agonist |
| Price (monthly) | $249/mo — all doses same price | $297/mo — all doses same price |
| 12-Month Bundle | $158/mo (save 37%) | $167/mo (save 44%) |
| Trial (avg weight loss) | 14.9% — STEP-1 (68 weeks) | 22.5% — SURMOUNT-1 (72 weeks) |
| ≥20% weight loss | 50.5% of patients | 57% of patients at 15mg |
| Formats Available | Injectable + oral (same price) | Injectable + oral (same price) |
| Cardiovascular data | SELECT: −20% MACE (2023) | Cardiovascular trial ongoing |
| FDA-approved version | Wegovy® (RxSvc: $99/mo) | Zepbound® (RxSvc: $99/mo) |
| Best for | Well-studied choice, CV risk patients | Maximum weight loss, insulin resistance |
Bottom Line: Tirzepatide wins on average weight loss (22.5% vs 14.9%) and metabolic outcomes at a modest $48/mo premium. Semaglutide wins on years of clinical study, cardiovascular event data (SELECT trial), and price. Both are available in injectable and oral form at Tmates with all dosages same price.
Mechanism: Why Tirzepatide Produces More Weight Loss
The fundamental difference between semaglutide and tirzepatide is the number of receptor pathways activated. Tmates GLP-1 program's compounded semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — it mimics the gut hormone that signals fullness, slows gastric emptying, and reduces food noise through hypothalamic GLP-1 receptors. This is a powerful and well-validated mechanism: STEP-1 documented 14.9% average weight loss at 68 weeks. But it is a single pathway.
Tmates' compounded GLP-1's compounded tirzepatide simultaneously activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are densely expressed in adipose tissue and peripheral metabolic organs, complementing GLP-1's hypothalamic appetite effects with enhanced adipose fat metabolism, peripheral insulin sensitivity, and comprehensive metabolic regulation. The additive effect of two synchronized receptor pathways is why SURMOUNT-1 documented 22.5% average weight loss at 72 weeks — 7.6 percentage points more than semaglutide. For a 250-pound patient, that difference is approximately 19 pounds.
Clinical Trial Data: STEP-1 vs SURMOUNT-1
STEP-1 (Semaglutide, NEJM 2021): 1,961 adults with obesity, 68 weeks, 2.4mg weekly dose. Average weight loss: 14.9%. Patients achieving ≥5% weight loss: 86.4%. ≥10%: 69.1%. ≥15%: 50.5%. ≥20%: not reported as primary endpoint. Placebo: 2.4% average weight loss.
SURMOUNT-1 (Tirzepatide, NEJM 2022): 2,539 adults with obesity, 72 weeks. Average weight loss by dose: 5mg: 15.0% | 10mg: 19.5% | 15mg (maximum): 22.5%. ≥5%: 96% of 15mg patients. ≥20%: 57% of 15mg patients. ≥25%: 36% of 15mg patients. Placebo: 2.5%. The 22.5% average is the largest pharmacological weight loss result in clinical history. For a real-world perspective, a 2023 JAMA Internal Medicine analysis of 18,386 patients confirmed tirzepatide's superiority over semaglutide in clinical practice settings across all subgroups.
Cardiovascular data: Semaglutide has the SELECT trial (NEJM 2023) — 20% reduction in major adverse cardiovascular events (MACE) in overweight adults without diabetes. This is unique to semaglutide in 2026; tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. For patients with established cardiovascular disease or significant cardiovascular risk factors, semaglutide's cardiac evidence base is a meaningful clinical advantage.
Who Should Choose Semaglutide at $249/mo
Semaglutide is the right choice if: you have established cardiovascular disease or high cardiovascular risk where SELECT trial data provides extra clinical rationale; you have tried multiple GLP-1 approaches and want the most studied medication; you are at the lower end of eligible BMI range and the $48/month difference matters meaningfully to your budget; or your physician's assessment of your intake profile points toward semaglutide. The 12-month bundle at $158/mo makes a full year of semaglutide for $1,900 — less than two months of brand-name Wegovy® at retail price. Read the phentermine vs semaglutide comparison if you're evaluating more affordable non-GLP-1 options.
Who Should Choose Tirzepatide at $297/mo
Tirzepatide is the right choice if: you want maximum weight loss from the most pharmacologically advanced available option; you have insulin resistance, metabolic syndrome, PCOS, or prediabetes where GIP's metabolic benefits beyond appetite are clinically relevant; you have a significant amount of weight to lose (BMI ≥35) where the 7.6 percentage point difference in clinical trials translates to meaningful additional pounds; or your physician advises starting with the stronger mechanism. See condition-specific guidance: GLP-1 for metabolic syndrome, GLP-1 for PCOS, GLP-1 for prediabetes. For the brand-name version, see the Zepbound® Rx service at $99/mo.
Pricing Summary: 12-Month Programs
Semaglutide 12-month program: $158/mo — saves 37% vs monthly. Tirzepatide 12-month program: $167/mo — saves 44% vs monthly. The gap narrows significantly at annual bundles: just $9/month difference between the two at their 12-month rates. For patients committed to a full year, the clinical argument for tirzepatide is compelling at the bundled price. Read the full Tmates pricing guide for all plans. Compare platforms: Tmates vs Medvi, Tmates vs TrimRx.
🏥 Ready to Start Your Treatment?
Get Semaglutide or Tirzepatide through Tmates — free shipping, licensed physicians, all 50 states.
Get Started with Tmates →